首页> 外文期刊>Der Pharmacia Lettre >Formulation design, optimization and evaluation of domperidone maleategastro retentive floating tablets
【24h】

Formulation design, optimization and evaluation of domperidone maleategastro retentive floating tablets

机译:马来酸多潘立酮固性漂浮片的配方设计,优化与评价

获取原文
       

摘要

The main objective of present research work is to formulate the of Domperidone Maleate floating tablets. Domperidone Maleate, an antiemetic and a prokinetic agent belongs to BCS Class-II and Indicated for treatment of upper gastrointestinal motility disorders by blocking the action of Dopamine. The Floating tablets of Domperidone Maleate were prepared employing different concentrations of HPMCK4M and Guar Gum in different combinations as a release rate modifiers by Direct Compression technique using 32 factorial design. The concentration of HPMCK4M and Guar Gum was selected as independent variables, X1 and X2 respectively whereas, time required for drug dissolution t10%, t50%,t75%,t90%were selected as dependent variables. Totally nine formulations were designed and are evaluated for hardness, friability, thickness, Assay, Floating Lag time, In-vitro drug release. From the Results concluded that all the formulation were found to be with in the Pharmacopoeial limits and the In-vitro dissolution profiles of all formulations were fitted in to different Kinetic models, the statistical parameters like intercept (a), slope (b) & regression coefficient (r) were calculated. Polynomial equations were developed for t10%, t50%, t75%, t90%. Validity of developed polynomial equations were verified by designing 2 check point formulations(C1, C2). According to SUPAC guidelines the formulation (F5) containing combination of 18.75% HPMCK4M and 18.75% Guar Gum, is the most similar formulation (similarity factor f2=89.03, dissimilarity factor f1= 11.539& No significant difference, t= 0.169) to marketed product (DOMSTAL OD). The selected formulation (F5) follows Higuchi’s kinetics, and the mechanism of drug release was found to be Non-Fickian Diffusion (n= 0.925).
机译:目前研究工作的主要目的是配制马来酸多潘立酮漂浮片。马来酸多潘立酮是一种止吐药和促动力药,属于BCS II类,适用于通过阻断多巴胺的作用来治疗上消化道运动障碍。通过使用32因子设计的直接压缩技术,以不同组合使用不同浓度的HPMCK4M和瓜尔胶作为释放速率调节剂来制备马来酸多潘立酮的漂浮片剂。选择HPMCK4M和瓜尔胶的浓度作为自变量,分别为X1和X2,而将药物溶解所需的时间t10%,t50%,t75%,t90%作为因变量。总共设计了9种配方,并对硬度,脆性,厚度,含量,漂浮滞后时间,体外药物释放进行了评估。从结果得出的结论是,发现所有制剂均符合药典限制,并且所有制剂的体外溶出度均适用于不同的动力学模型,其统计参数如截距(a),斜率(b)和回归计算系数(r)。针对t10%,t50%,t75%,t90%开发了多项式方程。通过设计2个检查点公式(C1,C2)验证了开发的多项式方程的有效性。根据SUPAC指南,与市场产品最相似的配方(F5)包含18.75%HPMCK4M和18.75%瓜尔胶的组合(相似系数f2 = 89.03,相异系数f1 = 11.539,无显着差异,t = 0.169) (DOMSTAL OD)。选择的配方(F5)遵循Higuchi的动力学,发现药物释放的机理是非菲克扩散(n = 0.925)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号